secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001104659-26-047735
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals appoints Andrew C. Chan to board; Scott Morrison resigns
-------------------------------------------------------------------------------

- Andrew C. Chan appointed as Class II director, effective April 23, 2026, term through 2027 annual meeting.
- Chan receives $35,000 annual retainer, $4,000 Nominating Committee fee, and initial option for 30,000 shares.
- Scott Morrison resigned from board effective April 23, 2026 after over a decade of service.
- Chan also appointed to the Nominating Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926047735/0001104659-26-047735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926047735/crvs-20260422x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-047735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer